14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
PHG vs CHEK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PHG Overall Winner
6-Pillar Tally: PHG 6 – 0 CHEK
Matrix Metrics: PHG 9 – 1 CHEK
As of Nov 20, 2026, Koninklijke Philips N.V. (PHG) is the stronger overall head-to-head candidate over Check-Cap Ltd. (CHEK) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PHG carries a Unified Composite Score of 40.3/100 (SELL) at $28.61 (14.0x Forward P/E, 8.8% operating margin), whereas CHEK carries 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While CHEK currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. PHG 40.3/100 SELL), PHG captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (8.8% vs. 0.0% operating margin) and revenue trajectory (+2.1% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PHG vs CHEK. Trailing 12-month operating profitability (PHG 8.8% vs CHEK 0.0%) and valuation multiples (PHG 14.0x vs CHEK N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $28.6B market capitalization and 8.8% operating margin.
OpEx & R&D Reinvestment37.6% of Rev ($6.68B)
90D Engineering Disclosures0 Published
CHEK Moat ProfileCyclical / Execution-Driven Positioning
X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator
Competes within the X-Ray Apparatus & Tubes & Related Irradiation Apparatus value chain with $9.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PHG vs CHEK Key Questions & Quantitative Answers
As of Nov 20, 2026, Koninklijke Philips N.V. (PHG) is the stronger overall head-to-head candidate over Check-Cap Ltd. (CHEK) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PHG carries a Unified Composite Score of 40.3/100 (SELL) at $28.61 (14.0x Forward P/E, 8.8% operating margin), whereas CHEK carries 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CHEK currently prints a higher short-term Unified Composite Score (52.1/100 HOLD vs. PHG 40.3/100 SELL), PHG captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (8.8% vs. 0.0% operating margin) and revenue trajectory (+2.1% vs. +0.0% YoY).
PHG leads the Growth & Scale pillar: PHG posts +2.1% YoY revenue growth and -85.4% YoY earnings growth on $17.8B TTM revenue (46.4% gross margin, 8.8% operating margin), compared with CHEK at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PHG generates $17.8B in USD-normalized revenue versus N/A for CHEK. In operating R&D and SG&A reinvestment, PHG deploys 37.6% of Rev ($6.68B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CHEK.
PHG screens cheaper on headline valuation multiples. PHG trades at 14.0x Forward P/E, 25.4x Trailing P/E, 0.90x PEG, and 1.9x EV/Revenue (10.3% FCF margin), whereas CHEK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PHG (8.6% ROE) versus CHEK (-226.2% ROE) capital efficiency.
In options market volatility and institutional positioning, PHG carries 111.5% implied volatility (51st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.71β · 38% Vol realized risk). By comparison, CHEK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 179% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.